Antibiotic Gatiflo to be withdrawn from market by Handok

Published: 2008-10-07 06:59:00

Updated: 2008-10-07 06:59:00

Handok Pharm announced on September 30 that it would stop selling Gatiflo (gatifloxacin), an antibiotic that has been associated with hyperglycemia and hypoglycemia, both of which are potentially fatal blood-sugar disorders.

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK